The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man — LVKGR  

Insulin Resistance Clinical Trial

Official title: The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man

Status Recruiting

Clinical Trial Summary

To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.

Clinical Trial Description

The investigators have previously demonstrated that infusion of the pentapeptide during hyperglycemic clamps in dogs significantly increases the glucose infusion rate necessary to maintain stable hyperglycemia without any significant differences in insulin or glucagon secretion. The present study's aim is to examine whether this also occurs in humans. It may be necessary to examine a dose response curve. Specifically, in twenty healthy volunteers glucose infusion rate during the peptide infusion will be compared to the glucose infusion rate during saline administration during a 4 hour hyperglycemic clamp, in a cross over design(mg/kg/min). ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Insulin Resistance

• NCT number: NCT02518932
• Study type: Interventional
• Source: Elahi, Dariush, PhD
• Contact: Dariush E;ahi, PhD
• Phone: 210-283-4520
• Email: dariush.elahi@iconplc.com
• Status: Recruiting
• Phase: Phase 1
• Start date: March 2015
• Completion date: March 2016